Open access · CC-BY
via OpenAlex
Mesenchymal Stem Cell Therapy for Aging Frailty
Ivonne Hernandez Schulman, Wayne Balkan, Joshua M. Hare
Frontiers in Nutrition · 2018 · ▲ 67 citations
Stem-cell exhaustion
Chronic inflammation
Stem-cell therapy
Exercise
Human
Randomized controlled trial
Abstract
Chronic diseases and degenerative conditions are strongly linked with the geriatric syndrome of frailty and account for a disproportionate percentage of the health care budget. Frailty increases the risk of falls, hospitalization, institutionalization, disability, and death. By definition, frailty syndrome is characterized by declines in lean body mass, strength, endurance, balance, gait speed, activity and energy levels, and organ physiologic reserve. Collectively, these changes lead to the loss of homeostasis and capability to withstand stressors and resulting vulnerabilities. There is a strong link between frailty, inflammation, and the impaired ability to repair tissue injury due to decreases in endogenous stem cell production. Although exercise and nutritional supplementation provide benefit to frail patients, there are currently no specific therapies for frailty. Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) provide therapeutic benefits in heart failure patients irrespective of age. MSCs contribute to cellular repair and tissue regeneration through their multilineage differentiation capacity, immunomodulatory, and anti-inflammatory effects, homing and migratory capacity to injury sites, and stimulatory effect on endogenous tissue progenitors. The advantages of using MSCs as a therapeutic strategy include standardization of isolation and culture expansion techniques and safety in allogeneic transplantation. Based on this evidence, we performed a randomized, double-blinded, dose-finding study in elderly, frail individuals and showed that intravenously delivered allogeneic MSCs are safe and produce significant improvements in physical performance measures and inflammatory biomarkers. We thus propose that frailty can be treated and the link between frailty and chronic inflammation offers a potential therapeutic target, addressable by cell therapy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fnut.2018.00108
- Canonical
- link ↗
- Fetched
- 2026-08-27 MST
Cite this
APA
Schulman, I.H., Balkan, W., & Hare, J.M. (2018). Mesenchymal Stem Cell Therapy for Aging Frailty. <em>Frontiers in Nutrition</em>. https://doi.org/10.3389/fnut.2018.00108
Vancouver
Schulman IH, Balkan W, Hare JM. Mesenchymal Stem Cell Therapy for Aging Frailty. Frontiers in Nutrition. 2018. doi:10.3389/fnut.2018.00108.
BibTeX
@article{ivonne2018Mesenc,
title = {Mesenchymal Stem Cell Therapy for Aging Frailty},
author = {Ivonne Hernandez Schulman and Wayne Balkan and Joshua M. Hare},
journal = {Frontiers in Nutrition},
year = {2018},
doi = {10.3389/fnut.2018.00108},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in aging 2026
Open access · OA
Mesenchymal stem cell senescence as a potency brake: causes, consequences, and cures.
Ageless Regenerative Institute 2011
Open access · US-GOV
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Intra-venous Implantation of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome
The Journals of Gerontology Series A 2018
Citation only
Mesenchymal Stem Cells for Periodontal Tissue Regeneration in Elderly Patients
The Journals of Gerontology Series A 2017
Open access · CC-BY
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial
The Foundation for Orthopaedics and Regenerative Medicine 2022
Open access · US-GOV
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty
Stem Cells and Cloning Advances and Applications 2015
Open access · CC-BY